Cargando…

Safety and clinical efficacy of human rabies immunoglobulin in post exposure prophylaxis for category III animal exposures

The human rabies immunoglobulin (HRIG) is a life-saving immune biological essential for all category III animal exposures. It provides neutralizing antibodies at the site of exposure until the body can produce vaccine-mediated antibodies. We conducted this study to determine the safety and clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haradanhalli, Ravish S., Fotedar, Nidhi, Kumari, Nitu, Narayana, D. H. Ashwath
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Licensed Vaccines – Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621008/ https://www.ncbi.nlm.nih.gov/pubmed/35687876 http://dx.doi.org/10.1080/21645515.2022.2081024

Ejemplares similares

An open-label, non-randomized study investigating the safety and efficacy of smallpox vaccine, LC16, as post-exposure prophylaxis for mpox
por: Tomita, Noriko, et al.
Publicado: (2023)

Letter to the editor: Safety and immunogenicity of a novel recombinant rabies vaccine
por: Agarwal, Anurag, et al.
Publicado: (2022)

Advances in the progress of monoclonal antibodies for rabies
por: Fan, Linlin, et al.
Publicado: (2022)

Commentary on the implications of safety and efficacy studies in pediatric patients with administration of human rabies immune globulin (HRIG)?
por: Siegel, Jerry, et al.
Publicado: (2022)

Immunogenicity and safety of reduced-antigen tetanus, diphtheria and acellular pertussis vaccination in adults treated for obstructive airway diseases
por: Van den Steen, Peter, et al.
Publicado: (2023)

Immunogenicity and safety of a live attenuated varicella vaccine co-administered with inactive hepatitis A vaccine: A phase 4, single-center, randomized, controlled trial
por: Sun, Dapeng, et al.
Publicado: (2023)

ASVAC2022 : 8(th) Asian Vaccine Conference
por: Galagoda, Geethani C. S., et al.
Publicado: (2023)

Mumps-specific antibody persistence in children aged 3–7 years immunized with two doses of mumps-containing vaccines: A prospective cohort study in Jiangsu Province, China
por: Sun, Jinfang, et al.
Publicado: (2023)

Public health impact of herpes zoster vaccination on older adults in Hong Kong
por: Chan, Paul K. S., et al.
Publicado: (2023)

Penta- and hexavalent vaccination of extremely and very-to-moderate preterm infants born at less than 34 weeks and/or under 1500 g: A systematic literature review
por: Knuf, Markus, et al.
Publicado: (2023)

Trends in research related to vaccine and cancer prevention from 1992 to 2022: A 30-years bibliometric analysis
por: Zhang, Luofei, et al.
Publicado: (2023)

Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries
por: George, Marina, et al.
Publicado: (2023)

Seroprevalence rates in children aged 3-6 years after implementing a two-dose varicella vaccination: A observational study
por: Zhang, Zhuoyu, et al.
Publicado: (2023)

Cross-reactive humoral immunity of clade 2 Oka and MAV/06 strain-based varicella vaccines against different clades of varicella–zoster virus
por: Hwang, Ji-Young, et al.
Publicado: (2023)

Measles vaccine uptake among Italian medical students compared to the pre-COVID-19 era
por: Ferrari, Cristiana, et al.
Publicado: (2023)

Measles vaccine uptake and COVID-19
por: Daungsupawong, Hinpetch, et al.
Publicado: (2023)

Improving Tdap maternal immunization rate in Saudi Arabia
por: Aldoosari, Agariad, et al.
Publicado: (2023)

Rabies immunoglobulin should not be forgotten in category III exposure
por: Gozdas, Hasan Tahsin
Publicado: (2021)

Immunogenicity and safety of human diploid cell vaccine (HDCV) vs. purified Vero cell vaccine (PVRV) vs. purified chick embryo cell vaccine (PCECV) used in post-exposure prophylaxis: a systematic review and meta-analysis
por: Wang, Shi-Yuan, et al.
Publicado: (2022)

A simulated, randomized study on the safety and immunogenicity of three consecutive commercial-scale batches of the CTN-1V strain human rabies vaccine to verify the inter-batch consistency
por: Zhou, Lei, et al.
Publicado: (2022)

Safety and immunogenicity of a combined DTacP-sIPV-Hib vaccine in animal models
por: Zhang, Yuntao, et al.
Publicado: (2022)

Re-thinking yellow fever vaccines: fighting old foes with new generation vaccines
por: Montalvo Zurbia-Flores, Gerardo, et al.
Publicado: (2021)

The progress of postapproval clinical studies on Sabin IPV
por: Shi, Li, et al.
Publicado: (2021)

Gaps in knowledge about the vaccine coverage of immunocompromised children: a scoping review
por: MacDonald, Shannon E., et al.
Publicado: (2021)

Maternal vaccines: ten considerations for vaccine introduction and scale-up in low- and middle-income countries from the maternal, newborn, child, and adolescent health perspective
por: Khan, Sadaf, et al.
Publicado: (2021)

Vaccination in preterm and low birth weight infants in India
por: Soans, Santosh, et al.
Publicado: (2021)

Burden of vaccine-preventable diseases among at-risk adult populations in the US
por: Kolobova, Irina, et al.
Publicado: (2022)

Response to a letter to the editor regarding ‘ the comparison of seroconversion rates among different varicella vaccines administered Turkish children; MAV/06 and vOka’
por: Sahbudak Bal, Zumrut, et al.
Publicado: (2022)

Seroprevalence comparison of different varicella vaccines among Turkish children
por: Choi, BongKyoo, et al.
Publicado: (2022)

The world’s largest measles-Rubella vaccination campaign in Pakistan: Time to invest in routine immunization
por: Rana, Muhammad Suleman, et al.
Publicado: (2022)

Waning rate of immunity and duration of protective immunity against diphtheria toxoid as a function of age and number of doses: Systematic review and quantitative data analysis
por: Kitamura, Noriko, et al.
Publicado: (2022)

Letter to the editor: Correspondence on Chinese medical personnel vaccinations
por: Sekhar, Sejal C., et al.
Publicado: (2022)

Available evidence and potential for vaccines for reduction in antibiotic prescriptions
por: Gabutti, Giovanni
Publicado: (2022)

Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants
por: Gao, Shuyu, et al.
Publicado: (2022)

Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure
por: Kang, Gagandeep, et al.
Publicado: (2023)

Safety evaluation on concomitant immunization with inactivated poliomyelitis vaccine produced from Sabin strains and other vaccines (from 2015 to 2020)
por: Deng, Yan, et al.
Publicado: (2022)

Safety profile comparison of chimeric live attenuated and Vero cell-derived inactivated Japanese encephalitis vaccines through an active surveillance system in Australia
por: Islam, Nazmul, et al.
Publicado: (2022)

Safety and immunogenicity of single dose live attenuated varicella vaccine (VR 795 Oka strain) in healthy Indian children: A randomized controlled study
por: Mitra, Monjori, et al.
Publicado: (2015)

A randomized trial assessing the efficacy, immunogenicity, and safety of vaccination with live attenuated varicella zoster virus-containing vaccines: ten-year follow-up in Russian children
por: Namazova-Baranova, Leyla, et al.
Publicado: (2021)

Safety, immunogenicity and non-interference of concomitant Typhoid Vi capsular polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV®) and measles or measles-mumps-rubella vaccines in 8–9 months-old Indian children
por: Vadrevu, Krishna Mohan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tefp5jlvlq75taltqv97ipa3dr